

# Expansion of donor-derived hematopoietic stem cells with PIGA mutation associated with late graft failure after allogeneic stem cell transplantation.

著者	Mochizuki Kanako, Sugimori Chiharu, Qi Zhirong, Lu Xuzhang, Takami Akiyoshi, Ishiyama Ken, Kondo Yukio, Yamazaki Hirohito, Okumura Hirokazu, Nakao Shinji
journal or publication title	Blood
volume	112
number	5
page range	2160-2162
year	2008-09-01
URL	<a href="http://hdl.handle.net/2297/12164">http://hdl.handle.net/2297/12164</a>

doi: 10.1182/blood-2008-02-141325

**Expansion of a donor-derived hematopoietic stem cell with *PIG-A* mutation associated with late graft failure after allogeneic stem cell transplantation.**

Short title: *PIG-A* mutant stem cell expansion with LGF

Kanako Mochizuki, Chiharu Sugimori, Zhirong Qi, Xuzhang Lu, Akiyoshi Takami, Ken Ishiyama, Yukio Kondo, Hirohito Yamazaki, Hirokazu Okumura, and Shinji Nakao

From Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, Ishikawa, Japan.

**Corresponding author:** Shinji Nakao, Cellular Transplantation Biology, Division of Cancer Medicine, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan; Phone: +81 76 265 2274. Fax: +81 76 234 4252; E-mail: [snakao@med3.m.kanazawa-u.ac.jp](mailto:snakao@med3.m.kanazawa-u.ac.jp)

## **Abstract**

A small population of CD55<sup>-</sup>CD59<sup>-</sup> blood cells was detected in a patient who developed donor-type late graft failure after allogeneic stem cell transplantation (SCT) for treatment of aplastic anemia (AA). Chimerism and *PIG-A* gene analyses showed the paroxysmal nocturnal hemoglobinuria (PNH)-type granulocytes to be of a donor-derived stem cell with a thymine insertion in *PIG-A* exon 2. A sensitive mutation-specific PCR-based analysis detected the mutation exclusively in DNA derived from the donor bone marrow (BM) cells. The patient responded to immunosuppressive therapy and achieved transfusion independence. The small population of PNH-type cells was undetectable in any of the 50 SCT recipients showing stable engraftment. The *de novo* development of donor-cell derived AA with a small population of PNH-type cells in this patient supports the concept that glycosyl phosphatidylinositol anchored protein deficient stem cells have a survival advantage in the setting of immune mediated BM injury.

## **Introduction**

Although small populations of CD55<sup>-</sup>CD59<sup>-</sup> blood cells are often detectable in patients with aplastic anemia (AA), it remains unclear how such paroxysmal nocturnal hemoglobinuria (PNH)-type cells arise.<sup>1</sup> We recently encountered a patient with immune-mediated late graft failure (LGF) following allogeneic stem cell transplantation (SCT) for treatment of AA. Analyses of the the patient's peripheral blood (PB) and bone marrow (BM) showed an HSC of donor origin with mutant *PIG-A*, supporting the concept that glycosyl phosphatidylinositol anchored protein (GPI-AP) deficient stem cells have a survival advantage in the setting of immune mediated BM injury.

## **Materials and methods**

### **Patients**

A 59-year-old male underwent allogeneic PBSCT from an HLA-matched sibling donor after conditioning with fludarabin 120 mg/m<sup>2</sup>, cyclophosphamide 1200 mg/m<sup>2</sup>, and antithymocyte globulin 60 mg/kg for treatment of very severe AA in April 2002 (Table 1) and achieved complete donor chimerism with normal blood cell counts. In January 2006, he developed pancytopenia and was diagnosed as having LGF without residual recipient cells. The patient underwent a second PBSCT from the original donor without preconditioning on February 8, 2006. Pancytopenia

resolved completely by day 16 post PBSCT. However, at approximately day 60, the blood counts decreased gradually, and the patient became transfusion dependent. On day 196 after the second PBSCT, the WBC was  $5.3 \times 10^9$  /L with 17% neutrophils, the Hb concentration was 75 g/L, and the platelet count was  $22 \times 10^9$  /L. Treatment with horse antithymocyte globulin (ATG) and cyclosporine was started on day 205 after the second PBSCT. Transfusions were terminated after 88 days of the immunosuppressive therapy. Although he presently receives low-dose tacrolimus for treatment of chronic graft-versus host disease which developed 1 year after the second PBSCT, his pancytopenia has markedly improved as shown in Table 1. PB and BM of the patient were subjected to analyses of chimerism, flow cytometry to detect CD55<sup>+</sup>CD59<sup>-</sup> cells, and *PIG-A* gene analysis.

As controls, the PB from 51 SCT recipients (48 with hematologic malignancies and 3 with AA) who achieved a complete recovery of donor-derived hematopoiesis were subjected to flow cytometric analysis for the screening of CD55<sup>+</sup>CD59<sup>-</sup> cells. Of the 51 patients, 4 and 23, respectively had acute graft-versus-host disease (GVHD)  $\geq$  grade II and chronic GVGD at sampling.

BM aspirates were obtained from the patient's donor and 10 healthy individuals for *PIG-A* gene analysis. All patients and healthy individuals gave their informed consent according to the Declaration of Helsinki for blood examination, and the experimental protocol for *PIG-A* gene analysis

was approved by our participating institutional ethics committee (No.157).

### **Detection of PNH-type cells**

To detect GPI-AP deficient (GPI-AP<sup>-</sup>), PNH-type cells, we performed high-sensitivity 2-color flow cytometry of granulocytes and red blood cells (RBCs), as described previously.<sup>1</sup> The presence of  $\geq 0.003\%$

CD55<sup>-</sup>CD59<sup>-</sup>CD11b<sup>+</sup> granulocytes and  $\geq 0.005\%$

CD55<sup>-</sup>CD59<sup>-</sup>glycophorin-A<sup>+</sup> RBCs was defined as an abnormal increase based on the results in 183 healthy individuals.<sup>2</sup>

### **Cell sorting and chimerism analysis**

CD3<sup>+</sup> cells were isolated from the PB mononuclear cells of the patient using MACS CD3 Microbeads (Miltenyi Biotec, Auburn, CA). The

CD55<sup>-</sup>CD59<sup>-</sup>CD11b<sup>+</sup> granulocytes were separated from the

CD55<sup>+</sup>CD59<sup>+</sup>CD11b<sup>+</sup> granulocytes with a cell sorter (JSAN; Bay

Bioscience Co., Ltd., Yokohama, Japan). More than 95% of the sorted cells were CD55<sup>-</sup>CD59<sup>-</sup>CD11b<sup>+</sup>. The *D1S80* locus was amplified from DNA of different cell populations with an AmpliFLP D1S80 PCR Amplification Kit (Perkin-Elmer Cetus, Norwalk, CT).

### ***PIG-A* gene analysis**

The coding regions of *PIG-A* were amplified by semi-nested PCR or nested PCR from DNA extracted from the sorted PNH-type cells using 12 primer sets<sup>3,4</sup> (Supplemental table online), and 6 ligation reactions were used to transform competent *Escherichia coli* JM109 cells (Nippon Gene, Tokyo,

Japan). Five clones were selected randomly from each group of transfectants and subjected to sequencing with a BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems).

### **Amplification refractory mutation system (ARMS)-PCR**

On the basis of a mutant sequence detected in *PIG-A* of the patient, a nested amplification refractory mutation system (ARMS) forward primer with a 3'-terminal nucleotide sequence complementary to the mutant sequence was prepared<sup>5</sup> (Supplemental table online). To enhance the specificity, a mismatch at the penultimate nucleotide position of the mutation site was incorporated in the ARMS forward primer (P1).<sup>6,7</sup> P1 and a reverse primer (P3) were used to amplify a 127 bp fragment containing the mutant sequence from the exon 2 amplified product. PCR was conducted under the following conditions; denaturation for 30 seconds at 94 °C, annealing for 60 seconds at 64 °C and extension for 90 seconds at 72 °C for 20 cycles. Another forward primer (P2), complementary to the wild-type *PIG-A* sequence upstream of the mutation site, was used in combination with P3 to amplify an internal control according to the same condition of ARMS-PCR.

### **Results and discussion**

PNH-type cells were not detected in the donor or the patient at the time

of development of the first LGF, whereas 0.147% PNH-type granulocytes and 0.019% PNH-type RBCs were detected in the PB obtained at the time of development of the second LGF (Figure 1A). Similar percentages of PNH-type blood cells were detectable in the PB of the patient 6 and 14 months later. When PB from 51 SCT recipients was examined, none of the patients were found to have detectable PNH-type cells (data not shown). PNH-type blood cells were also undetectable in a donor PB sample obtained 21 months later.

The *DIS80* locus allelic pattern of the PNH-type granulocytes in the patient was compatible to that of the donor (Figure 1B). The emergence of donor-derived PNH-type cells and hematologic improvement after immunosuppressive therapy suggest that LGF arises as a result of de novo development of AA which affects the donor-derived hematopoietic stem cells (HSCs).

*PIG-A* gene analysis of the DNA prepared from the sorted PNH-type cells of the patient obtained at the development of LGF and 6 months later showed an insertion of thymine at position 593 (codon 198) in 3 of 5 clones and 5 of 5 clones examined, respectively (Figure 1C). Mutations in other exons were not identified. The presence of a single *PIG-A* mutation in PNH-type granulocytes and its persistence over 6 months suggests that these PNH-type cells are derived from a mutant HSC rather than from a committed granulocyte progenitor cell. Moreover, an ARMS-PCR with a 5'



primer specific to the mutated sequence amplified a 127 bp fragment from DNA of the donor BM as well as of the recipient BM and PB while it failed to amplify the same fragment in donor PB and in BM of all 10 healthy individuals (Figure 1D).

These experiments demonstrate that the *PIG-A* mutant HSC was present in the BM of the donor in a dormant state and was transplanted into the recipient and provide, for the first time, *in vivo* evidence that *PIG-A* mutant, GPI-AP deficient HSCs have a survival advantage in the setting of immune mediated BM injury. Similarly, relative resistance to immune injury likely accounts for the high incidence of PNH observed in association with acquired AA.

## **Acknowledgments**

We thank Ms. Shizuka Yasue, Ms. Megumi Yoshii, and Ms. Rie Oumi for their excellent technical assistance. We also thank Dr. Charles Parker for his critical reading of this manuscript.

## **Authorship**

**Author contribution:** K.M. and C.S. contributed equally to this work and participated in designing and performing the research. Z.Q. and X.L. performed experiments. K.M., C.S., and S.N. wrote the paper. C.S., A.T., K.I., Y.K., H.Y., and H.O. provided patient care. All authors have

approved the final version of the manuscript.

**Conflict-of-interest disclosure:** The authors declare no competing financial interests.

**Grant support:** This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No.15390298), a grant from the Ministry of Health, Labour and Welfare of Japan, and a grant from the Japan Intractable Diseases Research Foundation.

## References

1. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. *Blood*. 2006;107:1308-1314.
2. Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1 \*1501 and DRB1 \*1502 in the pathogenesis of aplastic anemia. *Exp Hematol*. 2007;35:13-20.
3. Kai T, Shichishima T, Noji H, et al. Phenotypes and phosphatidylinositol glycan-class A gene abnormalities during cell differentiation and maturation from precursor cells to mature granulocytes in patients with paroxysmal nocturnal hemoglobinuria. *Blood*. 2002;100:3812-3818.
4. Mortazavi Y, Merk B, McIntosh J, et al. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. *Blood*. 2003;101:2833-2841.
5. Newton CR, Graham A, Heptinstall LE, et al. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). *Nucleic Acids Res*. 1989;17:2503-2516.
6. Dang RK, Anthony RS, Craig JI, Leonard RC, Parker AC. Limitations of the use of single base changes in the p53 gene to detect minimal residual disease of breast cancer. *Mol Pathol*. 2002;55:177-181.
7. Bai RK, Wong LJ. Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory mutation system quantitative PCR analysis: a single-step approach. *Clin Chem*. 2004;50:996-1001.

## Figure legends

### **Figure1. Analysis of PNH-type cells after the second PBSCT. (A)**

High-sensitivity flow cytometry detected small populations of CD55<sup>-</sup>CD59<sup>-</sup> cells in both granulocytes and red blood cells at the development of the second LGF as well as in those obtained 6 and 12 months later, but did not detect PNH-type cells in the donor or in the recipient before the second PBSCT. The numbers denote the proportion of PNH-type cells in CD11b<sup>+</sup> granulocytes or glycophorin A<sup>+</sup> RBCs. (B)

*DIS80* allelic patterns of sorted GPI-AP<sup>-</sup> granulocytes, GPI-AP<sup>+</sup> granulocytes, and CD3<sup>+</sup> lymphocytes. The polymerase chain reaction (PCR) products were subjected to 8% polyacrylamide gel electrophoresis and visualized by silver staining. (C) Nucleotide sequences of *PIG-A* exon 2 in DNA from PNH-type granulocytes obtained 6 and 12 months after the second PBSCT. (D) A schematic illustration for ARMS-PCR is shown.

Primer positions for the first, second are shown by short arrows. A black box and adjacent lines represent exon 2 and introns, respectively. (E)


Amplified products of control PCR (the upper gel) and ARMS-PCR (the lower gel) were electrophoresed in 12.5% polyacrylamide gel and visualized by the silver staining. A pMD20-T vector containing the mutated exon 2 fragment was used as a positive control for ARMS-PCR. The template DNA derives from a plasmid containing the mutated exon 2 in lane 1, donor BM in lane 2, donor PB in lane 3, recipient BM in lane 4,

recipient PB in lane 5, and BM from healthy individuals in lanes 6-11. PCR with a 5' primer specific to the nucleotide sequence upstream of the mutated sequence amplified a 261 bp fragment from DNA of the donor and all healthy individuals.

Table1 Hematologic parameters of donor and recipient.

	Donor		Recipient			
	Apr 2002	May 2007	Before 1st SCT Apr 2002	Before 2nd SCT Jan 2006	at ATG therapy Aug 2006	20 months of ATG therapy Apr 2008
White Blood Cell Count, $\times 10^9/\text{L}$	7.0	5.1	1.2	1.7	5.3	4.0
Neutrophil Proportions (%)	77	65	0	0	17	62
Red Blood Cell Count, $\times 10^{12}/\text{L}$	4.21	4.43	2.20	2.75	2.07	3.04
Reticulocytes, $\times 10^9/\text{L}$	not tested	35	2	3	26	61
Hemoglobin, g/L	146	150	72	89	75	120
Platelet Count, $\times 10^9/\text{L}$	261	230	19	52	22	54

Figure 1



## Supplemental table PCR primers

Primer	Sequence 5' → 3'	Location	Annealing	Product size, bp
			Temperature, °C	
1st PCR primers				
2-1F*	GAGCTGAGATCCTGTTTTAC	intron1	58.0	625
2-1R*	GTATCACAAAGAGACACGG	exon2	58.0	-
2-2F*	CATTGCTCAGGTACATATTGTT	exon2	58.0	421
2-2R*	AAAGTCTACAATGCAATTATAGC	intron2	58.0	-
3F*	AAGTGGATTCTCAGTCGTTCTGGT	intron2	58.0	247
3R*	CTTCTCCCTCAAGACAACATGAA	intron3	58.0	-
4F	ACTCCTTTCTTCCCCTCTCATT	intron3	58.0	206
4R	CACAGAAATCCCAACCATGAAT	intron4	58.0	-
5F†	TCTTCCTGAGGTATGATTATGGTG	intron4	58.0	306
5R	CATCAAGTAAGAGTTCAGACACAAT	intron5	58.0	-
6F†	GTCATTGTTTATCATGGGACAG	intron5	58.0	360
6R†	TCTTACAATCTAGGCTTCCTTC	exon6	58.0	-
2nd (nested or semi-nested) PCR primers				
2-1F*	GAGCTGAGATCCTGTTTTAC	intron1	60.0	598
2-1R2	TTGTTTGTAAGCACCGAG	exon2	60.0	-
2-2F2	GAGAGAGTCACGATAATCCA	exon2	60.0	395
2-2R*	AAAGTCTACAATGCAATTATAGC	intron2	60.0	-
3F2	ATTAATATCTCCAACATTCAACTTT	intron2	60.0	203
3R*	CTTCTCCCTCAAGACAACATGAA	intron3	60.0	-
4F	ACTCCTTTCTTCCCCTCTCATT	intron3	60.0	193
4R2	ACCATGAATGCCCTCAAAGC	intron4	60.0	-
5F2	GATTATGGTGGAGTATGTGTTC	intron4	60.0	269
5R2	ATCTTTTCTCAGCATGTGAC	intron5	60.0	-
6F2	TGATGGGTGAAAGTGCTC	intron5	60.0	329
6R†	TCTTACAATCTAGGCTTCCTTC	exon6	60.0	-
ARMS-PCR Primers				
P1	ACTGTACTAAGAGCAGCAGTT	exon2	64.0	127
P2	TTCAGACAGTCTTCACGG	exon2	64.0	261
P3	GTCTGCTGACAACAACAATAG	exon2	64.0	-

\* primers derived from a reference by Kai et al.<sup>3</sup>

† primers derived from a reference by Mortazavi et al.<sup>4</sup>